A triosmium carbonyl cluster that inhibits α-synuclein aggregation and disassembles preformed aggregates

Abstract

Two triosmium carbonyl clusters, viz., Os₃(μ-H)(μ-SC₆H₄-p-NO₂)(CO)₁₀ (1) and Os₃(μ-H)(kO,μ-O′-2-flavone)(CO)₉ (2), effectively inhibited α-synuclein aggregation, a key signature of Parkinson's disease (PD), in both wild-type and A53T-mutant α-synuclein models. Cluster 2 showed superior efficacy and a significantly better safety profile, and could also disassemble preformed aggregates.